ARRY Share Price

Open 8.69 Change Price %
High 9.05 1 Day 0.36 4.16
Low 8.68 1 Week 0.03 0.33
Close 9.01 1 Month 0.77 9.34
Volume 3362889 1 Year 5.63 166.57
52 Week High 13.40
52 Week Low 3.10
ARRY Important Levels
Resistance 2 9.35
Resistance 1 9.21
Pivot 8.91
Support 1 8.81
Support 2 8.67
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
VRTA 4.50 38.46%
ATEA 2.50 32.98%
ATEA 2.50 32.98%
KIRK 10.98 31.03%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TWER 0.10 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Array BioPharma Inc. (NASDAQ: ARRY)

ARRY Technical Analysis 4
As on 22nd Aug 2017 ARRY Share Price closed @ 9.01 and we RECOMMEND Buy for LONG-TERM with Stoploss of 8.52 & Strong Buy for SHORT-TERM with Stoploss of 8.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
ARRY Target for August
1st Target up-side 8.45
2nd Target up-side 9.11
3rd Target up-side 9.77
1st Target down-side 6.57
2nd Target down-side 5.91
3rd Target down-side 5.25
ARRY Other Details
Segment EQ
Market Capital 412133344.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.arraybiopharma.com
ARRY Address
ARRY
3200 Walnut Street
Boulder, CO 80301
United States
Phone: 303-381-6600
Fax: 303-449-5376
ARRY Latest News
Interactive Technical Analysis Chart Array BioPharma Inc. ( ARRY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Array BioPharma Inc.
ARRY Business Profile
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614. In December 2009, the Company granted Amgen, the global rights to the small molecule glucokinase activator program, including, AMG 151. Glucokinase activators (GKAs), such as AMG 151, represents a new class of drugs for the treatment of Type 2 diabetes. Glucokinase (GK) is the enzyme that senses glucose in the pancreas. GK also increases glucose utilization and decreases glucose production in the liver. In 2009, the Company completed a phase I trial to evaluate AMG 151 in a single ascending dose study in Type 2 diabetic patients. During the fiscal year ended June 30, 2010 (fiscal 2010), the Company initiated two Phase 1 studies, a multiple ascending dose (MAD), trail in patients with Type 2 diabetes to evaluate safety, exposure and glucose control over a 10-day period and a relative bioavailability study assessing the effect of food and formulation on exposure. In April 2010, the Company granted Novartis under a License Agreement with the global right to develop and commercialize MEK162, which is in a Phase I cancer trial, as well as ARRY-300 and other specified MEK inhibitors. Under the agreement, the Company is responsible for completing the on-going Phase I clinical trial of MEK162 and might conduct further development of MEK162 in colorectal cancer. In fiscal 2010, the Company initiated a Phase I dose escalation trial of MEK162 in cancer patients and established the maximum tolerated dose.